Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?
Year: 2020
Type: editorial
Abstract: The majority of cancer patients assume concomitant medications for the treatment of cancer-related symptoms or co-morbidities. As immune checkpoint inhibitors expand in the treatment of a widening range of malignancies, drug-drug interactions have become an area of increasing interest due to the potential for some concomitant medications to exert immune-modulatory effects and influence outcomes from immunotherapy. Here, we review the evidence supporting this association across selected drug classes including antibiotics, proton pump inhibitors, metformin, and opioids.
Authors: Nadiya Hussain, Muntaha Naeem, David J. Pinato
Institutions: Hammersmith Hospital, Imperial College London
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Award: G2921181837
OpenAlex ID: W3037219982
